A Multicenter Study of CAR-T Cells in Primary Ph+All

This study tests CAR-T cell therapy in patients who are newly diagnosed with a type of leukemia called Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ALL). CAR-T cells are immune cells genetically engineered to find and destroy leukemia cells bearing CD19 and CD22 proteins. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Ph+ALL and your leukemia cells test positive for both CD19 and CD22, and are positive for the Philadelphia chromosome - You have not yet received standard chemotherapy for this leukemia - Your heart, liver, kidney, and lung function meet the required levels - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have a history of epilepsy or other serious brain/nervous system conditions - You have a history of heart rhythm problems (QT interval prolongation) or severe heart disease - You are pregnant or breastfeeding - You have an untreated active infection - You have active or untreated hepatitis B or C, HIV, or syphilis - You have previously received any gene therapy product Talk to your doctor to see if this trial is right for you.